+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.

Age: 18Years +All GendersPhase 3
68 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.

Age: 40Years +All GendersPhase 3
411 locations
C

Actively Recruiting

Chemotherapy-induced peripheral neuropathy CIPN causes chronic nerve pain affecting up to 70% of cancer patients after chemotherapy. This pain impacts quality of life and daily functioning. Duloxetine is currently the only recommended medication to reduce CIPN pain, but its effect is modest. Methadone, an opioid with unique properties, may offer better pain control and less tolerance over time, but it has not yet been studied for CIPN treatment. This trial compares methadone and duloxetine for treating painful CIPN. Participants will be randomly assigned to receive either methadone or duloxetine for 5 weeks. Both drugs are given in capsules that look identical to maintain blinding. Weekly visits, either in person or virtual, will assess pain and side effects, and dosages will be adjusted as needed to control pain or until the 5-week period ends. During the study, participants will complete questionnaires about their pain and how it affects their function and quality of life. Researchers will monitor side effects and adjust doses weekly. The main measure is the change in average pain intensity over 5 weeks using a standard pain inventory. Other outcomes include effects on daily function, quality of life, and medication tolerance. Participants are followed closely throughout the treatment period, which lasts about 5 weeks.

Age: 19Years +All GendersPhase 2Phase 3
4 locations
A

Actively Recruiting

Researchers are evaluating new treatments for acute hypoxemic respiratory failure AHRF, a serious lung condition affecting millions worldwide and often leading to death or long-term health issues. This adaptive platform trial tests different interventions across varying severity levels, including non-intubated patients, those on mechanical ventilation, and patients needing extracorporeal life support. The study uses an advanced Bayesian design to efficiently assess multiple therapies and strategies, focusing on improving outcomes for critically ill patients. The trial includes several domains studying various therapies such as ultra-protective ventilation with extracorporeal CO2 removal, different mechanical ventilation strategies, corticosteroid use, and new drug treatments like fludrocortisone and nebulized furosemide. Interventions may involve adjusting ventilator settings, sedation, rehabilitation, or medication dosing over periods ranging from days to weeks. Some domains are observational and collect detailed biomarker and clinical data. The platform allows adding or dropping interventions based on ongoing results, optimizing research efficiency. Participants will undergo regular assessments including physiological and biological measurements, respiratory function tests, and monitoring of clinical outcomes like mortality, ventilator-free days, and organ function scores. Safety and adherence to protocols are closely tracked throughout. The study duration varies by intervention, with some domains enrolling patients over two years and monitoring outcomes up to six months. Participants may experience multiple visits for treatment adjustments, data collection, and follow-up evaluations.

Age: 18Years +All GendersPhase Not Applicable
103 locations